Valuation: Neuland Laboratories Limited

Market Cap 243B 2.54B 2.23B 2.08B 1.91B 3.58B 3.63B 24.69B 9.64B 120B 9.53B 9.32B 415B P/E 2027 *
58.1x
P/E 2028 * 42.1x
Enterprise Value 246B 2.57B 2.26B 2.1B 1.93B 3.63B 3.67B 24.99B 9.76B 122B 9.64B 9.44B 421B EV / Sales 2027 *
10.7x
EV / Sales 2028 * 8.83x
Free-Float
62.24%
Yield 2027 *
0.07%
Yield 2028 * 0.1%
1 day+2.42%
1 week+3.04%
Current month+2.23%
1 month+5.75%
3 months+31.86%
6 months+43.34%
Current year+25.17%
1 week 18,200
Extreme 18200
19,177
1 month 17,944
Extreme 17944
20,089
Current year 11,500
Extreme 11500
20,089
1 year 11,500
Extreme 11500
20,089
3 years 3,302.3
Extreme 3302.3
20,089
5 years 967
Extreme 967
20,089
10 years 245.75
Extreme 245.75
20,089
Manager TitleAgeSince
Chief Executive Officer 46 2026-03-31
Director of Finance/CFO - 2022-11-22
Chief Tech/Sci/R&D Officer - 2023-02-28
Director TitleAgeSince
Director/Board Member 50 2001-12-31
Chairman 82 1984-01-06
Director/Board Member 46 2007-02-28
Change 5-day change 1-year change 3-year change Capi.($)
+2.42%+3.04% - - 2.47B
+0.13%+1.56%+47.35%+164.01% 1,067B
+0.97%+5.10%+58.02%+53.98% 635B
-0.94%+0.95%+35.02%+81.05% 458B
+1.41%+7.75%+38.93%+32.88% 347B
+1.28%+2.82%+38.42%+43.21% 295B
+1.72%+2.33%+19.31%+20.79% 262B
+1.84%-1.03%-27.78%-38.45% 216B
+0.06%+2.72%+22.73%+59.97% 203B
+0.94%-2.80%+12.32%+69.09% 161B
Average +0.98%+1.33%+27.15%+54.06% 404.83B
Weighted average by Cap. +0.61%+1.95%+36.75%+79.84%

Financials

2027 *2028 *
Net sales 23.09B 241M 212M 197M 181M 340M 344M 2.34B 915M 11.4B 904M 884M 39.4B 27.8B 290M 255M 237M 218M 409M 414M 2.82B 1.1B 13.73B 1.09B 1.06B 47.44B
Net income 4.21B 43.91M 38.6M 35.93M 33M 61.96M 62.78M 427M 167M 2.08B 165M 161M 7.19B 5.81B 60.55M 53.23M 49.55M 45.5M 85.45M 86.57M 589M 230M 2.87B 227M 222M 9.91B
Net Debt 2.94B 30.63M 26.93M 25.07M 23.02M 43.23M 43.8M 298M 116M 1.45B 115M 113M 5.01B 1.92B 20.02M 17.6M 16.39M 15.05M 28.26M 28.63M 195M 76.07M 948M 75.17M 73.55M 3.28B
Logo Neuland Laboratories Limited
Neuland Laboratories Ltd. is a global provider of active pharmaceutical ingredients (APIs) contract development and manufacturing organization (CDMO) services. It is focused on manufacture and sale of active pharmaceutical ingredients and allied services. It supports biotechnology and pharmaceutical companies in the design, development and manufacturing of complex APIs. It has two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). It develops and manufactures non-exclusive APIs both Prime APIs comprising large volume, mature molecules, and specialty APIs comprising lower volume, complex molecules with less competition. It develops small molecules and peptides for clinical trials and beyond. It provides an end-to-end continuum of customized services from early-stage drug development (Pre-IND) through to commercial manufacturing of complex APIs, including process development, process optimization, analytical testing, and regulatory support.
Employees
2,183
Date Price Change Volume
26-07-27 ₹18,994.00 +2.42% 27,760
26-07-24 ₹18,546.00 +0.62% 11,320
26-07-23 ₹18,431.00 -0.19% 17,966
26-07-22 ₹18,466.00 -2.27% 17,420
26-07-21 ₹18,895.00 -0.28% 19,859
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
18,975.40INR
Average target price
21,222.00INR
Spread / Average Target
+11.84%

Quarterly revenue - Rate of surprise